AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2025
Apr 3, 2025
32407_dirs_2025-04-03_90708f4c-3808-45c6-8cb2-c3a5efa11a03.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-04-03
Reporting Person: Basta Steven L (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-03 | Performance Shares | $ | A | 360000 | Acquired | Common Stock (360000) | Direct | |
| 2025-04-03 | Stock Option (Right to Buy) | $5.01 | A | 1085000 | Acquired | 2035-04-02 | Common Stock (1085000) | Direct |
Footnotes
F1: Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date.
F3: The stock option will vest with respect to 25% of the shares of common stock on April 3, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.